Selected article for: "antiviral drug and drug library"
Author: Wang, Gan; Yang, Meng-Li; Duan, Zi-Lei; Liu, Feng-Liang; Jin, Lin; Long, Cheng-Bo; Zhang, Min; Tang, Xiao-Peng; Xu, Ling; Li, Ying-Chang; Kamau, Peter Muiruri; Yang, Lian; Liu, Hong-Qi; Xu, Jing-Wen; Chen, Jie-Kai; Zheng, Yong-Tang; Peng, Xiao-Zhong; Lai, Ren
Title: Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
  • Cord-id: tcu6vdjy
  • Document date: 2020_12_1
    • ID: tcu6vdjy
    Snippet: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic worldwide. Currently, however, no effective drug or vaccine is available to treat or prevent the resulting coronavirus disease 2019 (COVID-19). Here, we report our discovery of a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, based on virtual screening of the FDA-approved peptide drug library combined with in vitro and in vivo functional antiviral assays. Our re
    Document: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic worldwide. Currently, however, no effective drug or vaccine is available to treat or prevent the resulting coronavirus disease 2019 (COVID-19). Here, we report our discovery of a promising anti-COVID-19 drug candidate, the lipoglycopeptide antibiotic dalbavancin, based on virtual screening of the FDA-approved peptide drug library combined with in vitro and in vivo functional antiviral assays. Our results showed that dalbavancin directly binds to human angiotensin-converting enzyme 2 (ACE2) with high affinity, thereby blocking its interaction with the SARS-CoV-2 spike protein. Furthermore, dalbavancin effectively prevents SARS-CoV-2 replication in Vero E6 cells with an EC(50) of ~12 nM. In both mouse and rhesus macaque models, viral replication and histopathological injuries caused by SARS-CoV-2 infection are significantly inhibited by dalbavancin administration. Given its high safety and long plasma half-life (8–10 days) shown in previous clinical trials, our data indicate that dalbavancin is a promising anti-COVID-19 drug candidate.

    Search related documents:
    Co phrase search for related documents
    • acetate buffer and acute sars cov respiratory syndrome coronavirus: 1
    • acetate buffer and luciferase activity: 1
    • activate site and acute sars cov respiratory syndrome coronavirus: 1
    • activate surface and acute sars cov respiratory syndrome coronavirus: 1
    • activate surface and luciferase activity: 1
    • acute sars cov respiratory syndrome coronavirus and addition time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and load analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute sars cov respiratory syndrome coronavirus and loading dose: 1, 2
    • acute sars cov respiratory syndrome coronavirus and long half rhesus life: 1
    • acute sars cov respiratory syndrome coronavirus and long plasma: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • addition time and load analysis: 1
    • addition time and luciferase activity: 1, 2, 3
    • addition time experiment and luciferase activity: 1